Nothing Special   »   [go: up one dir, main page]

US5208146A - Murine monoclonal anti-idiotype antibodies - Google Patents

Murine monoclonal anti-idiotype antibodies Download PDF

Info

Publication number
US5208146A
US5208146A US07/609,255 US60925590A US5208146A US 5208146 A US5208146 A US 5208146A US 60925590 A US60925590 A US 60925590A US 5208146 A US5208146 A US 5208146A
Authority
US
United States
Prior art keywords
human
antibodies
antibody
idiotype
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/609,255
Inventor
Reiko F. Irie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to US07/609,255 priority Critical patent/US5208146A/en
Assigned to REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE reassignment REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: IRIE, REIKO F.
Application granted granted Critical
Publication of US5208146A publication Critical patent/US5208146A/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Assignors: UNIVERSITY OF CALIFORNIA
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF CALIFORNIA LOS ANGELES
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Definitions

  • the present invention relates generally to anti-idiotype monoclonal antibodies and their use as surrogate antigens, immunomodulators, immunosuppressants and immunodiagnostic agents More particularly, the present invention involves murine monoclonal anti-idiotype antibodies which are developed against a human monoclonal antibody reactive to cancer cells. The present invention not only involves use of the anti-idiotype antibodies, but also includes the cell line which produce the anti-idiotype antibodies.
  • variable regions of immunoglobulins could act as external antigens.
  • recognition of idiotypes on the antigen-combining site, or on the framework of AB1 results in the production of anti-idiotypes (anti-ids or AB2) beta and alpha, respectively.
  • anti-idiotypes anti-ids or AB2
  • Such "internal image" anti-idiotypes by virtue of their complementarity with the original antigen binding site, mimic the original antigen and often behave in a similar biological manner.
  • the concept of internal image refers to the fact that some AB2 molecules can act as surrogate antigens and their administration can lead to the production of anti-anti-idiotype antibodies displaying similar characteristics of AB1.
  • anti-ids as surrogate antigens has generated much interest among researchers, many of whom have experimented with AB2 vaccines for active specific immunization against viruses, bacteria, and other pathogens (2,3). This approach is useful when a conventional vaccine or antibodies are not available, or are difficult to produce or when the corresponding antigen is not a suitable product for genetic engineering.
  • anti-ids can be used as immunomodulators for up-regulating immunity against cancer, and as immunosuppressants to prevent rejection of transplanted organs and to prevent the progression of auto-immune disease.
  • Gangliosides are glycospingolipids that are fundamental membrane components on human tissues. Gangliosides undergo characteristic changes during malignant transformation of normal cells and thus are desirable target antigens for immunotherapy of cancer. Melanoma synthesizes a large number of gangliosides and thus has served as a useful model to assess the potential of gangliosides as immunotherapy targets. A number of tumor-associated gangliosoides of human melanoma and their respective immonogenicity have been defined (12-29). In addition, it has been shown that active immunization with ganglioside antigens results in prolonged survival of melanoma patients (4,5). Nevertheless, this technique suffers in many areas, namely that the ganglioside antigen are many times rare or in short supply.
  • Tumor-associated antigens in most cases, are present in nature only at low levels and are relatively difficult to purify in large amounts. In contrast, anti-ids can be secreted from hybridoma cells at low cost over long periods of time. Furthermore, current genetic engineering technology, while not applicable to ganglioside epitopes, can be used to synthesize the anti-id peptides. Anti-ids previously developed for active specific immunotherapy of human cancer have used murine monoclonal antibodies (MuMabs) as the immunogens (6-11).
  • Murine monoclonal antibodies have also been employed to define and characterize many antigenic molecules on human cancer cells.
  • Murine monoclonal antibodies have several advantages over human monoclonal antibodies including a strong affinity for tumor antigens, higher antibody secretion by hybridoma ascites, and high antigen density on tumor cells.
  • human monoclonal antibodies HuMAbs
  • HuMAbs human monoclonal antibodies
  • HuMAbs may be preferable since repeated injections of MuMAbs induce anti-murine Ig antibodies in virtually all patients. This leads to formation of immune complexes and immune reactions with potentially hazardous complications.
  • HuMAbs may recognize epitopes that are overlooked by the murine immune system.
  • HuMAbs that react with ganglioside antigens on human cancer cells and the demonstration of their anti-tumor effect at the clinical level has been reported (23,12).
  • Patients with recurrent melanoma received intratumor injections of HuMAb to ganglioside GD2 or GM2, and partial or complete regression was observed in about 70% of the patients.
  • the target antigen GD2 or GM2 was not expressed on the tumor cells.
  • immunological assays which have been used to detect the quality and quantity of gangliosides present on a given tumor. They include: the immune adherence assay (IA); direct immunofluoresence with fluorescinated microspheres; and IA absorption, and a biochemical assay. These assays each have certain limitations and advantages.
  • the immunologic assay requires single cell suspensions from the biopsied tumor tissues. However, it is often difficult to obtain viable high yield tumor cell populations. Also, under a light microscope, tumor cells may not be readily distinguished from monocytes and macrophages.
  • the biochemical assay does not require intact cells. However, a relatively large volume of tumor is necessary for ganglioside extraction and measurement of sialic acid in the glycolipid preparation.
  • the most commonly utilized immunologic technique for defining antigen expression on biopsy specimens using murine monoclonal antibodies is immunohistochemical staining of tissue sections.
  • this sensitive method is not readily applicable to combinations of human monoclonal antibodies and human tissues.
  • the indirect staining of human tumor tissues with the second antibody (anti-human Ig) usually results in high background from non-specific binding to abundant endogenous human Ig.
  • Direct immunostaining using biotinylated human monoclonal antibodies may overcome this high background (30).
  • this method is usually less sensitive and is most effective when a high density antigen is present on the cell surface.
  • a new group of murine monoclonal anti-idiotype antibodies has been discovered which mimics the sialic acid-galactose residue of tumor gangliosides. It was discovered that the beta-type anti-ids in accordance with the present invention are useful as a surrogate antigen for use in treating cancers such as melanoma. It was further discovered that the alpha-type anti-ids in accordance with the present invention are useful in immunohistochemical staining procedures to provide sensitive and specific detection of gangliosides present on tumor cells.
  • the anti-idiotype antibodies in accordance with the present invention are raised against a human monoclonal anti-ganglioside antibody which is identified as L612.
  • the L612 antibody is produced by a B-lymphoblastoid cell line which is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the anti-idiotype antibodies in accordance with the present invention may be either an alpha-type or a beta-type. Both types are produced in relatively large quantities by hybridoma cell lines.
  • a particularly suitable hybridoma cell line identified as 4C10 has been developed for producing beta-type anti-ids in accordance with the present invention.
  • the 4C10 hybridoma cell line is maintained at the division of Surgical Oncology at the University of California at Los Angeles School of Medicine and has been deposited at the American Type Culture Collection under ATCC assession number HB10722 on Apr. 4, 1991 (12301 Parklawn Drive, Rockville, Md. 20852).
  • the beta-type monoclonal anti-id produced by the 4C10 hybridoma is expected to be useful in treating melanoma tumors.
  • a second hybridoma cell line has been isolated which is particularly well-suited for producing alpha-type monoclonal anti-ids in accordance with the present invention.
  • This hybridoma cell line has been identified as 18C6 and is also presently maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the 18C6 hybridoma cell line has been deposited at the American Type Culture Collection under ATCC assession number HB10723 on Apr. 4, 1991.
  • the alpha-type anti-id produced by the 18C6 hybridoma cell line has been found to be useful in improving the specificity of immunohistochemical staining of tissue sections to determine which gangliosides are present on tumor cells.
  • the anti-idiotype antibodies (anti-ids) in accordance with the present invention are mouse IgG(Kappa) monoclonal antibodies which are raised to the monoclonal antibody identified as L612 which is secreted by the human B-cell line that is also identified as L612 and which is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • L612 cell line has been deposited at the American Type Culture, Collection under ATCC accession number CRL10724 on Apr. 4, 1991.
  • the L612 cell line was established in culture from lymphocytes by the Epstein-Barr virus transformation technique used to produce two other human monoclonal anti-ganglioside antibodies, L55 (anti-GM2) and L72 (anti-GD2) (26-27).
  • the L612 monoclonal antibody reacts strongly with human melanoma tumor biopsies.
  • the L612 antibody also reacts less strongly with human tumor biopsies from lung cancer, breast cancer, pancreatic cancer, colon cancer and kidney cancer.
  • the UCLASO-M12 melanoma cell line was identified as the most reactive cell line among the lines tested with the L612 monoclonal antibody.
  • the UCLASO-M12 cell line is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the L612 cell line was initially grown in RPMI 1640 medium containing fetal bovine serum, but later was adapted to a serum free medium containing a growth factor (SGF-6S) in CEM 2000 from Scott Laboratories, (Carson, Calif.); or AIM medium from Gibco Laboratories, (Grand Island, N.Y.). Human IgM in the spent medium was purified as previously described (25).
  • anti-ids in accordance with the present invention are produced by hybridomas which are prepared according to the following exemplary procedure:
  • mice were immunized by a subcutaneous injection of 200 ug of purified L612 monoclonal antibody in complete Freund's adjuvant. After 2 weeks the animals were boosted by another subcutaneous injection of L612 in incomplete Freund's adjuvant. Eleven days following the booster, the mice were injected intraperitoneally with 200 ug of L612 in saline. After three days the spleens were removed and the splenocytes fused with myeloma cell line SP2/0 using the standard procedure to produce hybridomas.
  • Hybridomas secreting anti-ids were identified by their strong binding reactivity to HuMAb L612 and absent reactivity to three other control human IgMs: L55, L72, and human serum IgM. Unrelated proteins used as antigens included fetal bovine serum and human serum albumin. 50 ul of IgMs or proteins (50 ug/ml) were coated on a 96-well ELISA plate and served as antigens to detect AB2. Peroxidase-conjugated goat anti-mouse IgG+IgM was used as the AB2 detection probe followed by substrate and reading absorbancy at 490 nm as described previously (19).
  • the three assay systems were: IA inhibition, cell-ELISA inhibition, and GM3-ELISA inhibition. Of the 40 antibodies tested, seven inhibited L612 binding t o an antigen positive target melanoma cell line, (UCLASO-M12), and to GM3 greater than 50% in the assays, while 12 others had weak or no inhibitory activity.
  • ULASO-M12 an antigen positive target melanoma cell line
  • inhibitory anti-ids Of the seven inhibitory anti-ids, one identified as 4C10 was selected for cloning as the preferred beta-type anti-id for use in treating tumors. From the non-inhibitory group the anti-id identified as 18C6 was selected for cloning as the preferred alpha-type anti-id for use in immunodiagnostic assays. Both anti-ids, 4C10 and 18C6, were tested with isotype antigloboulins and found to be of the IgG1 class and contain kappa light chains.
  • the 4C10 and 18C6 cloned hybridoma cell lines were grown in FCS-containing RPMI 1640 medium and secreted 5-10 ug/ml of antibody into culture supernatants. Titers of the anti-ids in these culture supernatants against L612 by ELISA ranged between 1:200 to 1:1000/10 6 hybridoma.
  • Anti-id 18C6 demonstrated low binding inhibition of HuMAb L612 to target cells in the IA assay (0%) and to ganglioside GM3 in ELISA (0%) whereas 4C10 at the same antibody concentration showed strong inhibition in both the ELISA assay (100%) and the IA assay (100%).
  • 4C10 and 18C6 failed to inhibit the binding of an unrelated antigen system, HuMAb L72, to M14 target cells, or to GD2 antigen.
  • the lack of binding inhibition of 18C6 indicates a binding location on L612 outside the GM3 antigen combining site, and the specific binding inhibition of 4C10 indicates its binding location to be within or near the antigen combining site.
  • the hybridoma cell lines which secrete the 4C10 and 18C6 monoclonal anti-ids are, as previously mentioned, being maintained at the Divsion of Surgical Oncology at the University of California at Los Angeles School of Medicine.
  • the 4C10 hybridoma cell line has been deposited at the American Type Culture Collection under ATCC accession number HB10722.
  • the 18C6 hybridoma cell line has also been deposited under ATCC accession number HB10723.
  • the 4C10 anti-id and other beta-type anti-ids in accordance with the present invention can be used alone or in combination with other agents to treat tumors. They are preferred for use in treating melanoma tumors. These beta-type anti-ids may also be used as an immunomodulator to enhance anti-cancer immunity, suppress organ transplant rejection and suppress autoimmune disease.
  • the beta-anti-ids of the present invention may be administered by any of the conventional procedures used to introduce antibodies into patients. These procedures include subcutaneous, intravenous or intratumor injection.
  • the beta-type anti-ids are preferrably conjugated with KLH and emulsified in a suitable carrier typically used for administration of antibodies.
  • the particular doses used for the beta-type anti-ids will vary depending upon the tumor being treated and numerous other factors.
  • the dosage levels are established by the known techniques and principles generally recognized and utilized in treating patients with antigen immunization agents or monoclonal antibodies.
  • mice Five syngeneic Balb/c mice were immunized with purified 4C10-KLH. As controls, four mice were immunized with mouse IgG1-KLH and one mouse with KLH alone. The immunized sera were monitored by ELISA using purified GM3 as the antigen source and by the IA assay using the antigen positive M12 melanoma cell line. In the ELISA, peroxidase conjugated goat anti-mouse IgM+IgG (Boeringer Mannheim) was used as a second antibody.
  • Measurable antibody was produced in three of the five immunizations with 100 ug 4C10-KLH.
  • the immunized sera bound to GM3 but not to CDH (asialo-GM3).
  • Sera from the control mice immunized with IgG-KLH or KLH alone gave no response to either glycolipid.
  • the majority of the reactivity was identified as IgM.
  • the immunized murine sera were pre-absorbed by human red blood cells at 4° C. overnight. An IA score of 4+ was obtained at 1:10 dilution of the absorbed sera. Control sera gave no reactivity even at 1:2 dilution.
  • IA inhibition was performed using GM3 (10 ug), CDH (10 ug), 4C10 (10 ug) and unrelated IgG1 (10 ug) purified from Balb/c hybridoma ascites. While reactivity was completely inhibited by GM3 or purified 4C10, no inhibition was obtained with CDH or unrelated IgG1.
  • beta-type anti-ids in accordance with the present invention produce AB3 anti-bodies which are immunoreactive with melanoma tumors. Accordingly, these beta-type anti-ids are expected to be effective as an immunization agent in the treatment of melanoma.
  • alpha-type anti-ids produced in accordance with the present invention are well-suited for use in immunodiagnostic procedures such as a three-step cell-ELISA procedure and a three step immunoperoxidase staining of tumor tissue sections. Examples of practice are as follows:
  • Viable M12 cells (1 ⁇ 10 5 ) were plated onto a U-bottom 960well microtiter plate (Immulon-1, Dynatec) after pre-blocking with 1% BSA-PBS. 50 ul of L612 (100 ug/ml) were added and incubated for 1 hour at room temperature. After washing the mixture to remove unbound HuMAb L612, the cells were incubated with murine monoclonal anti-id 18C6 (100 ug/ml) for 1 hour at room temperature. After washing, 50 ul of peroxidase-conjugated goat anti-mouse IgG antibody (1/10,000 diluted) (Jackson Immuno Research) were added and the plate was incubated for 30 minutes. After washing with PBS solution, the substrate for peroxidase was added and binding activity was determined as a function of absorbance at 490 nm with a V max kinetic microplate reader.
  • the cell bound L612 should have reduced its binding activity to anti-id beta, yet still retain full binding activity to anti-id alpha.
  • the above-described procedure confirmed this process using cultured M12 melanoma cells which express a high density of the corresponding antigen.
  • the above-described cell binding assay represents a modified form of the ELISA technique.
  • Control anti-ganglioside HuMAbs included L55 (IgM anti-GM2) and L72 (IgM anti-GD2), both of which exhibit strong binding ability to the GM2 and GD2 rich M14 melanoma cell line (26, 27).
  • the anti-id 18C6 reacted strongly to M12 cells after pre-incubation with HuMaB L6I2, but did not react to M14 cells that were pre-incubated with L55 or L72 HuMAb.
  • the peroxidase-conjugated anti-mouse Ig also failed to react with M12 cells in other controls including murine anti-id alone, L612, or L612 plus (anti-id beta).
  • the cell-ELISA assay was then applied to several other human tumor cell lines.
  • a two-step cell binding assay (HuMAb +peroxidase-conjugated anti-human IgM) was compared with the three-step cell-binding assay to evaluate the validity of the three-step assay.
  • the three-step assay had parallel reactivity with the two-step assay and was slightly more sensitive in almost every cell line. This data indicates that the ELISA absorbancy value of the three-step assay accurately reflects differences in the density of cell surface GM3 antigens and correlates closely with the two-step in vitro assays.
  • Tissue sections 4 um thick were cut from tissues freshly frozen in OTC compound and immediately fixed in cold formaldehyde buffer (12 g Tris buffer, 9 g sodium chloride, 40 ml 37% formaldehyde, pH 7.4) and air dried. Slides were dipped in Tris buffer for five minutes then treated with 3% hydrogen peroxide for 10 minutes to quench endogenous peroxidase activity.
  • HuMAb L612 (10 ug IgM in 200 ul) was then applied and incubated for 45 minutes.
  • the slides were washed in Tris buffer for 5 minutes, the purified anti-id 18C6 (10 ug IgG1 in 200 ul) was applied and incubated for 30 minutes.
  • the third antibody a biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, Calif.) at 1/100 dilution was applied and incubated for 25 minutes. Proxidase-conjugated streptavidin (1/1000 dilution) (Zymed Laboratories, San Francisco) was added after washing and incubated for 20 minutes. After washing, the slides were immersed in substrate solution containing 6 ml amino-ethyl carbazole, 50 ml of 0.02 M sodium acetate buffer (pH 5.1), and 0.4 ml of freshly prepared 3% hydrogen oxide for 5 minutes. The slides were washed once more in tap water, counterstained with hematoxoylin, and cover-slips applied to the stained sections using glycerol-gelatin.
  • substrate solution containing 6 ml amino-ethyl carbazole, 50 ml of 0.02 M sodium acetate buffer (pH 5.1), and 0.4 ml
  • the immunoperoxidase three-step assay described above was applied to surgically biopsied tumor tissues that had been snap frozen.
  • HuMAb L612 was found to react with 100% of nevus tissue (10/10), 100% of melanoma (14/14), 40% of lung caroinoma (2/5), and 33% of breast carcinoma (2/6) and 1 of one colon carcinoma. Positive reactivity was not seen in sarcomas (0/2) tested, nor in the normal skin tissues examined (0/3). Non-cancerous portions of antigen-positive tumor sections and a normal skin tissue were clearly negative. None of the tumor tissues were positive in the absence of L612. Specificity was further confirmed by an additional control experiment: positivie tissues were not stained when they were pre-treated with unrelated human monoclonal antibodies (L72 or L55 HuMAbs).
  • murine anti-id alpha in accordance with the present invention is a sensitive and specific probe for use in detecting huMAbs bound to biopsied tumor tissues and to identify expression of ganglioside antigens on biopsied human tissues.
  • the anti-ids in accordance with the present invention may be used to make chimeric antibodies which are also useful in a variety of treatments or as diagnostic reagents.
  • the anti-ids may also be used in other diagnostic procedures such as competitive binding assays. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.
  • Ganglioside GM2 on the K56 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40:12-17, 1987.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Murine monoclonal anti-idiotype antibodies raised against a human monoclonal anti-ganglioside antibody identified as L612. Both alpha and beta type anti-idiotype antibodies are disclosed which belong to the IgG1 class and contain kappa light chains. Two hybridoma cell lines which produced the monoclonal anti-idiotype antibodies are identified. The beta-type anti-idiotype antibodies are useful as an immunization agent to raise antibodies which are immunoreactive with tumors. The alpha-type anti-idiotype antibodies are useful as a probe for use in detecting human monoclonal antibodies bound to biopsied tumor tissues and to identify expression of ganglioside antigens on biopsied human tissues.

Description

This invention was made with Government support under Grant Nos. CA 30647, CA 42396 and CA 12582 awarded by the National Cancer Institute.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to anti-idiotype monoclonal antibodies and their use as surrogate antigens, immunomodulators, immunosuppressants and immunodiagnostic agents More particularly, the present invention involves murine monoclonal anti-idiotype antibodies which are developed against a human monoclonal antibody reactive to cancer cells. The present invention not only involves use of the anti-idiotype antibodies, but also includes the cell line which produce the anti-idiotype antibodies.
2. Description of Related Art
The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.
The possibility that the variable regions of immunoglobulins could act as external antigens was first recognized by Jerne in his idiotype network theory (1). According to this theory, recognition of idiotypes on the antigen-combining site, or on the framework of AB1, results in the production of anti-idiotypes (anti-ids or AB2) beta and alpha, respectively. Such "internal image" anti-idiotypes, by virtue of their complementarity with the original antigen binding site, mimic the original antigen and often behave in a similar biological manner. The concept of internal image refers to the fact that some AB2 molecules can act as surrogate antigens and their administration can lead to the production of anti-anti-idiotype antibodies displaying similar characteristics of AB1.
Immunization using anti-ids as surrogate antigens has generated much interest among researchers, many of whom have experimented with AB2 vaccines for active specific immunization against viruses, bacteria, and other pathogens (2,3). This approach is useful when a conventional vaccine or antibodies are not available, or are difficult to produce or when the corresponding antigen is not a suitable product for genetic engineering. In addition, anti-ids can be used as immunomodulators for up-regulating immunity against cancer, and as immunosuppressants to prevent rejection of transplanted organs and to prevent the progression of auto-immune disease.
Gangliosides are glycospingolipids that are fundamental membrane components on human tissues. Gangliosides undergo characteristic changes during malignant transformation of normal cells and thus are desirable target antigens for immunotherapy of cancer. Melanoma synthesizes a large number of gangliosides and thus has served as a useful model to assess the potential of gangliosides as immunotherapy targets. A number of tumor-associated gangliosoides of human melanoma and their respective immonogenicity have been defined (12-29). In addition, it has been shown that active immunization with ganglioside antigens results in prolonged survival of melanoma patients (4,5). Nevertheless, this technique suffers in many areas, namely that the ganglioside antigen are many times rare or in short supply.
Tumor-associated antigens, in most cases, are present in nature only at low levels and are relatively difficult to purify in large amounts. In contrast, anti-ids can be secreted from hybridoma cells at low cost over long periods of time. Furthermore, current genetic engineering technology, while not applicable to ganglioside epitopes, can be used to synthesize the anti-id peptides. Anti-ids previously developed for active specific immunotherapy of human cancer have used murine monoclonal antibodies (MuMabs) as the immunogens (6-11).
In addition to their use as surrogate antigens, murine monoclonal antibodies have also been employed to define and characterize many antigenic molecules on human cancer cells. Murine monoclonal antibodies have several advantages over human monoclonal antibodies including a strong affinity for tumor antigens, higher antibody secretion by hybridoma ascites, and high antigen density on tumor cells. However, with respect to therapeutic use, recent clinical trials with murine monoclonals have indicated that human monoclonal antibodies (HuMAbs) may be preferable since repeated injections of MuMAbs induce anti-murine Ig antibodies in virtually all patients. This leads to formation of immune complexes and immune reactions with potentially hazardous complications. In addition, HuMAbs may recognize epitopes that are overlooked by the murine immune system.
The development of HuMAbs that react with ganglioside antigens on human cancer cells and the demonstration of their anti-tumor effect at the clinical level has been reported (23,12). Patients with recurrent melanoma received intratumor injections of HuMAb to ganglioside GD2 or GM2, and partial or complete regression was observed in about 70% of the patients. In those melanoma patients in whom the immunotherapy was ineffective, the target antigen GD2 or GM2, was not expressed on the tumor cells.
Because the quantity and quality of gangliosides on human melanoma are widely heterogeneous between different cancer patients, it is desireable to avoid unnecessary administration of HuMAb by examination of a pre-treatment biopsy to identify which gangliosides dominate on each patient's tumor cells.
There are three different immunological assays which have been used to detect the quality and quantity of gangliosides present on a given tumor. They include: the immune adherence assay (IA); direct immunofluoresence with fluorescinated microspheres; and IA absorption, and a biochemical assay. These assays each have certain limitations and advantages. The immunologic assay requires single cell suspensions from the biopsied tumor tissues. However, it is often difficult to obtain viable high yield tumor cell populations. Also, under a light microscope, tumor cells may not be readily distinguished from monocytes and macrophages. The biochemical assay does not require intact cells. However, a relatively large volume of tumor is necessary for ganglioside extraction and measurement of sialic acid in the glycolipid preparation.
The most commonly utilized immunologic technique for defining antigen expression on biopsy specimens using murine monoclonal antibodies is immunohistochemical staining of tissue sections. However, this sensitive method is not readily applicable to combinations of human monoclonal antibodies and human tissues. The indirect staining of human tumor tissues with the second antibody (anti-human Ig) usually results in high background from non-specific binding to abundant endogenous human Ig. Direct immunostaining using biotinylated human monoclonal antibodies may overcome this high background (30). However, this method is usually less sensitive and is most effective when a high density antigen is present on the cell surface.
As is apparent from the above background, there presently is a need to provide additional types of anti-idiotype antibodies which can be used as surrogate antigens in treating tumors. There also is a need to provide an improved method for detecting the presence of specific antigens on human tumor tissue to aid in selecting which anti-ids, or other monoclonal antibodies are to be used in treatment.
SUMMARY OF THE INVENTION
In accordance with the present invention, a new group of murine monoclonal anti-idiotype antibodies has been discovered which mimics the sialic acid-galactose residue of tumor gangliosides. It was discovered that the beta-type anti-ids in accordance with the present invention are useful as a surrogate antigen for use in treating cancers such as melanoma. It was further discovered that the alpha-type anti-ids in accordance with the present invention are useful in immunohistochemical staining procedures to provide sensitive and specific detection of gangliosides present on tumor cells.
The anti-idiotype antibodies in accordance with the present invention are raised against a human monoclonal anti-ganglioside antibody which is identified as L612. The L612 antibody is produced by a B-lymphoblastoid cell line which is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
The anti-idiotype antibodies in accordance with the present invention may be either an alpha-type or a beta-type. Both types are produced in relatively large quantities by hybridoma cell lines. As a feature of the present invention, a particularly suitable hybridoma cell line identified as 4C10 has been developed for producing beta-type anti-ids in accordance with the present invention. The 4C10 hybridoma cell line is maintained at the division of Surgical Oncology at the University of California at Los Angeles School of Medicine and has been deposited at the American Type Culture Collection under ATCC assession number HB10722 on Apr. 4, 1991 (12301 Parklawn Drive, Rockville, Md. 20852). The beta-type monoclonal anti-id produced by the 4C10 hybridoma is expected to be useful in treating melanoma tumors.
As another feature of the present invention, a second hybridoma cell line has been isolated which is particularly well-suited for producing alpha-type monoclonal anti-ids in accordance with the present invention. This hybridoma cell line has been identified as 18C6 and is also presently maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine. The 18C6 hybridoma cell line has been deposited at the American Type Culture Collection under ATCC assession number HB10723 on Apr. 4, 1991. The alpha-type anti-id produced by the 18C6 hybridoma cell line has been found to be useful in improving the specificity of immunohistochemical staining of tissue sections to determine which gangliosides are present on tumor cells.
The above-described features along with many other features and attendant advantages of the present invention will become apparent as the invention becomes better understood by reference to the following detailed description.
DETAILED DESCRIPTION OF THE INVENTION
The anti-idiotype antibodies (anti-ids) in accordance with the present invention are mouse IgG(Kappa) monoclonal antibodies which are raised to the monoclonal antibody identified as L612 which is secreted by the human B-cell line that is also identified as L612 and which is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine. The L612 cell line has been deposited at the American Type Culture, Collection under ATCC accession number CRL10724 on Apr. 4, 1991.
The L612 cell line was established in culture from lymphocytes by the Epstein-Barr virus transformation technique used to produce two other human monoclonal anti-ganglioside antibodies, L55 (anti-GM2) and L72 (anti-GD2) (26-27). The L612 monoclonal antibody reacts strongly with human melanoma tumor biopsies. The L612 antibody also reacts less strongly with human tumor biopsies from lung cancer, breast cancer, pancreatic cancer, colon cancer and kidney cancer. The UCLASO-M12 melanoma cell line was identified as the most reactive cell line among the lines tested with the L612 monoclonal antibody. The UCLASO-M12 cell line is maintained at the Division of Surgical Oncology at the University of California at Los Angeles School of Medicine.
The L612 cell line was initially grown in RPMI 1640 medium containing fetal bovine serum, but later was adapted to a serum free medium containing a growth factor (SGF-6S) in CEM 2000 from Scott Laboratories, (Carson, Calif.); or AIM medium from Gibco Laboratories, (Grand Island, N.Y.). Human IgM in the spent medium was purified as previously described (25).
The anti-ids in accordance with the present invention are produced by hybridomas which are prepared according to the following exemplary procedure:
BALB/c mice were immunized by a subcutaneous injection of 200 ug of purified L612 monoclonal antibody in complete Freund's adjuvant. After 2 weeks the animals were boosted by another subcutaneous injection of L612 in incomplete Freund's adjuvant. Eleven days following the booster, the mice were injected intraperitoneally with 200 ug of L612 in saline. After three days the spleens were removed and the splenocytes fused with myeloma cell line SP2/0 using the standard procedure to produce hybridomas.
After HAT medium selection, hybridoma culture wells were tested for antibody using ELISA. Hybridomas secreting anti-ids (AB2) were identified by their strong binding reactivity to HuMAb L612 and absent reactivity to three other control human IgMs: L55, L72, and human serum IgM. Unrelated proteins used as antigens included fetal bovine serum and human serum albumin. 50 ul of IgMs or proteins (50 ug/ml) were coated on a 96-well ELISA plate and served as antigens to detect AB2. Peroxidase-conjugated goat anti-mouse IgG+IgM was used as the AB2 detection probe followed by substrate and reading absorbancy at 490 nm as described previously (19).
HAT selection of approximately 2500 hybridoma culture wells which were prepared as described above yielded 40 hybridomas secreting antibodies with distinct reactivity to L612 HuMAb, but no reactivity to three other control human IgMs and two unrelated serum protein antigens. To determine whether these anti-L612 antibodies were AB2 beta-type directed against the antigen combining site of L612, or were AB2 alpha antibodies bound to peptide regions outside the antigen-combining site of L612, the inhibitory activity of these anti-L612 antibodies against L612 binding to GM3 positive target cell lines or to the purified antigen, ganglioside GM3, was tested. Ganglioside GM3 includes a terminal sugar having NeuAc∝2-3 Galactose residue. The three assay systems were: IA inhibition, cell-ELISA inhibition, and GM3-ELISA inhibition. Of the 40 antibodies tested, seven inhibited L612 binding t o an antigen positive target melanoma cell line, (UCLASO-M12), and to GM3 greater than 50% in the assays, while 12 others had weak or no inhibitory activity.
Of the seven inhibitory anti-ids, one identified as 4C10 was selected for cloning as the preferred beta-type anti-id for use in treating tumors. From the non-inhibitory group the anti-id identified as 18C6 was selected for cloning as the preferred alpha-type anti-id for use in immunodiagnostic assays. Both anti-ids, 4C10 and 18C6, were tested with isotype antigloboulins and found to be of the IgG1 class and contain kappa light chains.
The 4C10 and 18C6 cloned hybridoma cell lines were grown in FCS-containing RPMI 1640 medium and secreted 5-10 ug/ml of antibody into culture supernatants. Titers of the anti-ids in these culture supernatants against L612 by ELISA ranged between 1:200 to 1:1000/106 hybridoma. Anti-id 18C6 demonstrated low binding inhibition of HuMAb L612 to target cells in the IA assay (0%) and to ganglioside GM3 in ELISA (0%) whereas 4C10 at the same antibody concentration showed strong inhibition in both the ELISA assay (100%) and the IA assay (100%). As a control assay, 4C10 and 18C6 failed to inhibit the binding of an unrelated antigen system, HuMAb L72, to M14 target cells, or to GD2 antigen. The lack of binding inhibition of 18C6 indicates a binding location on L612 outside the GM3 antigen combining site, and the specific binding inhibition of 4C10 indicates its binding location to be within or near the antigen combining site.
The hybridoma cell lines which secrete the 4C10 and 18C6 monoclonal anti-ids are, as previously mentioned, being maintained at the Divsion of Surgical Oncology at the University of California at Los Angeles School of Medicine. The 4C10 hybridoma cell line has been deposited at the American Type Culture Collection under ATCC accession number HB10722. The 18C6 hybridoma cell line has also been deposited under ATCC accession number HB10723.
The 4C10 anti-id and other beta-type anti-ids in accordance with the present invention can be used alone or in combination with other agents to treat tumors. They are preferred for use in treating melanoma tumors. These beta-type anti-ids may also be used as an immunomodulator to enhance anti-cancer immunity, suppress organ transplant rejection and suppress autoimmune disease.
The beta-anti-ids of the present invention may be administered by any of the conventional procedures used to introduce antibodies into patients. These procedures include subcutaneous, intravenous or intratumor injection. The beta-type anti-ids are preferrably conjugated with KLH and emulsified in a suitable carrier typically used for administration of antibodies. The particular doses used for the beta-type anti-ids will vary depending upon the tumor being treated and numerous other factors. The dosage levels are established by the known techniques and principles generally recognized and utilized in treating patients with antigen immunization agents or monoclonal antibodies.
The immunogenic usefulness of the beta-type anti-ids was demonstrated as follows:
Five syngeneic Balb/c mice were immunized with purified 4C10-KLH. As controls, four mice were immunized with mouse IgG1-KLH and one mouse with KLH alone. The immunized sera were monitored by ELISA using purified GM3 as the antigen source and by the IA assay using the antigen positive M12 melanoma cell line. In the ELISA, peroxidase conjugated goat anti-mouse IgM+IgG (Boeringer Mannheim) was used as a second antibody.
Measurable antibody (AB3) was produced in three of the five immunizations with 100 ug 4C10-KLH. The immunized sera bound to GM3 but not to CDH (asialo-GM3). Sera from the control mice immunized with IgG-KLH or KLH alone gave no response to either glycolipid. In further analysis to determine the Ig class of the AB3 (ELISA and TLC immunostaining), the majority of the reactivity was identified as IgM.
In order to exclude the species specific natural antibodies that might react to M12 cells in the IA assay, the immunized murine sera were pre-absorbed by human red blood cells at 4° C. overnight. An IA score of 4+ was obtained at 1:10 dilution of the absorbed sera. Control sera gave no reactivity even at 1:2 dilution. To confirm that the positive reactivity was directed against GM3 antigen on the cell surface, IA inhibition was performed using GM3 (10 ug), CDH (10 ug), 4C10 (10 ug) and unrelated IgG1 (10 ug) purified from Balb/c hybridoma ascites. While reactivity was completely inhibited by GM3 or purified 4C10, no inhibition was obtained with CDH or unrelated IgG1.
The above example demonstrates that beta-type anti-ids in accordance with the present invention produce AB3 anti-bodies which are immunoreactive with melanoma tumors. Accordingly, these beta-type anti-ids are expected to be effective as an immunization agent in the treatment of melanoma.
The alpha-type anti-ids produced in accordance with the present invention are well-suited for use in immunodiagnostic procedures such as a three-step cell-ELISA procedure and a three step immunoperoxidase staining of tumor tissue sections. Examples of practice are as follows:
Three-Step Cell-ELISA
Viable M12 cells (1×105) were plated onto a U-bottom 960well microtiter plate (Immulon-1, Dynatec) after pre-blocking with 1% BSA-PBS. 50 ul of L612 (100 ug/ml) were added and incubated for 1 hour at room temperature. After washing the mixture to remove unbound HuMAb L612, the cells were incubated with murine monoclonal anti-id 18C6 (100 ug/ml) for 1 hour at room temperature. After washing, 50 ul of peroxidase-conjugated goat anti-mouse IgG antibody (1/10,000 diluted) (Jackson Immuno Research) were added and the plate was incubated for 30 minutes. After washing with PBS solution, the substrate for peroxidase was added and binding activity was determined as a function of absorbance at 490 nm with a Vmax kinetic microplate reader.
When the antigen combining sites of L612 are occupied by GM3 expressed on tumor cells, the cell bound L612 should have reduced its binding activity to anti-id beta, yet still retain full binding activity to anti-id alpha. The above-described procedure confirmed this process using cultured M12 melanoma cells which express a high density of the corresponding antigen.
The above-described cell binding assay represents a modified form of the ELISA technique. Several control assays were included to establish the specificity of the positive reaction. Control anti-ganglioside HuMAbs included L55 (IgM anti-GM2) and L72 (IgM anti-GD2), both of which exhibit strong binding ability to the GM2 and GD2 rich M14 melanoma cell line (26, 27). The anti-id 18C6 reacted strongly to M12 cells after pre-incubation with HuMaB L6I2, but did not react to M14 cells that were pre-incubated with L55 or L72 HuMAb. The peroxidase-conjugated anti-mouse Ig also failed to react with M12 cells in other controls including murine anti-id alone, L612, or L612 plus (anti-id beta).
The cell-ELISA assay was then applied to several other human tumor cell lines. A two-step cell binding assay (HuMAb +peroxidase-conjugated anti-human IgM) was compared with the three-step cell-binding assay to evaluate the validity of the three-step assay. The three-step assay had parallel reactivity with the two-step assay and was slightly more sensitive in almost every cell line. This data indicates that the ELISA absorbancy value of the three-step assay accurately reflects differences in the density of cell surface GM3 antigens and correlates closely with the two-step in vitro assays.
Three-Step Immunoperoxidase Staining of Tissue Sections
Tissue sections 4 um thick were cut from tissues freshly frozen in OTC compound and immediately fixed in cold formaldehyde buffer (12 g Tris buffer, 9 g sodium chloride, 40 ml 37% formaldehyde, pH 7.4) and air dried. Slides were dipped in Tris buffer for five minutes then treated with 3% hydrogen peroxide for 10 minutes to quench endogenous peroxidase activity.
After washing in running water for five minutes, sections were overlaid with 5% normal human serum for 20 minutes. HuMAb L612 (10 ug IgM in 200 ul) was then applied and incubated for 45 minutes. The slides were washed in Tris buffer for 5 minutes, the purified anti-id 18C6 (10 ug IgG1 in 200 ul) was applied and incubated for 30 minutes.
After washing the slides again, the third antibody, a biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, Calif.) at 1/100 dilution was applied and incubated for 25 minutes. Proxidase-conjugated streptavidin (1/1000 dilution) (Zymed Laboratories, San Francisco) was added after washing and incubated for 20 minutes. After washing, the slides were immersed in substrate solution containing 6 ml amino-ethyl carbazole, 50 ml of 0.02 M sodium acetate buffer (pH 5.1), and 0.4 ml of freshly prepared 3% hydrogen oxide for 5 minutes. The slides were washed once more in tap water, counterstained with hematoxoylin, and cover-slips applied to the stained sections using glycerol-gelatin.
The immunoperoxidase three-step assay described above was applied to surgically biopsied tumor tissues that had been snap frozen. HuMAb L612 was found to react with 100% of nevus tissue (10/10), 100% of melanoma (14/14), 40% of lung caroinoma (2/5), and 33% of breast carcinoma (2/6) and 1 of one colon carcinoma. Positive reactivity was not seen in sarcomas (0/2) tested, nor in the normal skin tissues examined (0/3). Non-cancerous portions of antigen-positive tumor sections and a normal skin tissue were clearly negative. None of the tumor tissues were positive in the absence of L612. Specificity was further confirmed by an additional control experiment: positivie tissues were not stained when they were pre-treated with unrelated human monoclonal antibodies (L72 or L55 HuMAbs).
These above results show that murine anti-id alpha in accordance with the present invention is a sensitive and specific probe for use in detecting huMAbs bound to biopsied tumor tissues and to identify expression of ganglioside antigens on biopsied human tissues.
Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations and modifications may be made within the scope of the present invention. For example, the anti-ids in accordance with the present invention may be used to make chimeric antibodies which are also useful in a variety of treatments or as diagnostic reagents. The anti-ids may also be used in other diagnostic procedures such as competitive binding assays. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.
BIBLIOGRAPHY
1. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373-389, 1974.
2. Dalgleish AG, Kennedy RC. Anti-idiotype antibodies as immunogens: idiotype-based vaccines. Vaccine 6:215-220, 1962.
3. Sikorska HM. Therapeutic applications of anti-idiotypic antibodies. J Biol Res Mod 7:327-358, 1988.
4. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987.
5. Livingston PO. Experimental and clinical studies with active specific immunotherapy. In "Immunity to Cancer II." Eds MS Mitchell, Pub Alan L Liss, Inc, NY.
6. Herlyn D, Wettendorff M, Schmoll E. Anti-idiotype immunization of cancer patients: modulation of immune response. Proc Natl Acad Sci 84:8055-8059, 1987.
7. Bhattacharya-Chatterjee M, Pride MW, Seon BK, Kohler H. Idiotype vaccines against human T-cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes. J Immunol 139:1354-1360, 1987.
8. Viale G, Grassi F, Pelagi M, Alzani R, Menard S, Miotti S, Buffa R, Gina A, Siccardi AG. Anti-human tumor antibodies induced in mice and rabbits by "internal image" anti-idiotype monoclonal immunoglobulins. J Immunol 139:4250-4255, 1987.
9. Chen H, Mittelman A, Yamada M. Association of restricted specificity of anti-anti-idiotypic antibodies with prolonged survival of melanoma patients. Proc Amer Assoc Clin Oncol 8:A1125, 1989.
10. Kahn M, Hellstrom I, Estin CD, Hellstrom KE. Monoclonal anti-idiotypic antibodies related to the p97 melanoma antigen. Cancer Res 49:3157-3162, 1989.
11. Barth A, Waibel R, Stahei RA. Monoclonal anti-idiotypic antibody mimicking a tumor-associated sialoglycoprotein antigen induces humoral immune response against human small cell lung carcinoma. Int J Cancer 43:896-900, 1989.
12. Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-787, 1989.
13. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma II. Cancer, 623:1166-1174, 1989.
14. Ravindranath MH, Morton DL, Irie RF. An epitope common to ganglioside 0-acetyl AD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3691-3897, 1989.
15. Hoon DBS, Ando I, Sviland G, Tsuchida T, Okun E, Morton DL, Irie RF. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Int J Cancer 43:857-862, 1989.
16. Hoon DBS, Irie RF, Cochran AJ. Gangliosides from human melanoma immodulate response of T-cells to interleukin-2. Cell Immunol 111:410-419, 1988.
17. Ravindranath MH, Paulson JC, Irie RF. Human melanoma antigen 0-acetylated ganglioside GD3 is recognized by cancer autennarius lectin.1 J Biol Chem 263:2079-2086, 1988.
18. Tsuchida T, Ravindranath MH, Saxton RE, Irie RF. Gangliosides of human melanoma Altered expression in vivo and in vitro. Cancer Res 47:1278-1281, 1987.
19. Tai T, Sze LL, Kawashima I, Saxton RE, Irie RF. Monoclonal antibody detects monosialoganglioside having sialic acid 2-3 Galactosyl residue. J Biol Chem 262:6803-6807, 1987.
20. Ando I, Hoon DSB, Suzuki Y, Saxton RE, Golub SH, Irie RF. Ganglioside GM2 on the K56 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40:12-17, 1987.
21. Tsuchida T, Saxton RE, Irie RF. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55-60, 1987.
22. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54, 1987.
23. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci 83:8694-8698, 1986.
24. Katano M, Irie RF. Suppressed growth of human melanoma in nude mice by human monoclonal antibody to ganglioside GD2. Immunology Letters 8:169-174, 1984.
25. Katano M, Saxton RE, Irie RF. Human monoclonal antibody to tumor-associated ganglioside GD2. J Clin Lab Immunol 15:119-126, 1984.
26. Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci, USA 80:5392-5396, 1983.
27. Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of human neuroectodermal tumor antigen (OFA-I-1) as ganglioside GD2. Proc Natl Acad Sci 79:7629-7633, 1982.
28. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985.
29. Irie RF, Sze Ll, Saxton RE. Human antibody to OFA-I, tumor antigen produced in vitro by EBV-transformed human B-lymphoblastoic cell lines. Proc Natl Acad Sci 79:5666-5670, 1982.
30. Yano T, Yasumoto K, Nagashima A, Murakami H, Hashizume S and Nomoto K (1988) Immunohistological characterization of human monoclonal antibody against lung cancer. J Surg Oncol. 39, 108.

Claims (3)

What is claimed is:
1. A murine monoclonal anti-idiotype antibody raised against a human monoclonal anti-ganglioside antibody identified as L612 under ATCC accession number CRL10724 said anti-idiotype antibody including an antigenic determinant that mimics a sialic acid galactose residue of gangliosides present on tumors wherein said anti-idiotype antibody is an alpha-type anti-idiotype antibody produced by a hybridoma which is identified as 18C6 and which is deposited at the American Type Culture Collection under ATCC accession number HB10723.
2. A hybridoma which is identified as 18C6 and which is deposited at the American Type Culture Collection under ATCC accession number HB10723.
3. A method for detecting the presence of human monoclonal antibody bound to human tumor tissue comprising the steps of treating said human tumor tissue with an immunoreactive amount of anti-idiotype antibody for a sufficient time to allow said anti-idiotype antibody to bind to human monoclonal antibody; and detecting the presence of any anti-idiotype antibody which becomes bound to said human monoclonal antibody, wherein said anti-idiotype antibody is an alpha-type anti-idiotype antibody produced by a hybridoma which is identified as 18C6 and which is deposited at the American Type Culture Collection under ATCC accession number HB10723.
US07/609,255 1990-11-05 1990-11-05 Murine monoclonal anti-idiotype antibodies Expired - Fee Related US5208146A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/609,255 US5208146A (en) 1990-11-05 1990-11-05 Murine monoclonal anti-idiotype antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/609,255 US5208146A (en) 1990-11-05 1990-11-05 Murine monoclonal anti-idiotype antibodies

Publications (1)

Publication Number Publication Date
US5208146A true US5208146A (en) 1993-05-04

Family

ID=24439983

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/609,255 Expired - Fee Related US5208146A (en) 1990-11-05 1990-11-05 Murine monoclonal anti-idiotype antibodies

Country Status (1)

Country Link
US (1) US5208146A (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
EP0702082A1 (en) * 1993-10-06 1996-03-20 Hagiwara, Yoshihide Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and dna base sequences encoding those sequences
WO1996022373A2 (en) * 1995-01-17 1996-07-25 University Of Kentucky Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
WO1997019113A2 (en) * 1995-11-17 1997-05-29 Centro De Inmunologia Molecular (Cim) Monoclonal antiidiotypic antibodies (ab2) and uses thereof
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
WO2000029443A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
WO2001039788A2 (en) 1999-12-02 2001-06-07 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
US20020051103A1 (en) * 2000-06-26 2002-05-02 Faris Sadeg M. Backlight for a liquid crystal display having high light-recycling efficiency
US20020122795A1 (en) * 2000-12-08 2002-09-05 Paller Amy S. Compositions containing gangliosides for use in the treatment of skin disorders
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
US20030152575A1 (en) * 1997-06-13 2003-08-14 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20070071760A1 (en) * 2005-08-09 2007-03-29 Herve Broly Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US20070274984A1 (en) * 2006-05-15 2007-11-29 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
US20080003617A1 (en) * 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
EP2192132A2 (en) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2010073119A1 (en) * 2008-12-23 2010-07-01 Adocia Stable pharmaceutical composition containing at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
EP2241623A2 (en) 1999-07-07 2010-10-20 ZymoGenetics, Inc. Monoclonal antibody against a human cytokine receptor
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
US20110027337A1 (en) * 2007-12-21 2011-02-03 Ifxa A/S Protease inhibitor
US20110172166A1 (en) * 2009-12-23 2011-07-14 Adocia Anionic polysaccharides functionalized by a hydrophobic acid derivative
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2602263A2 (en) 2007-11-21 2013-06-12 Roskilde Universitet Polypeptides comprising an ice-binding activity
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
WO2016146134A1 (en) 2015-03-16 2016-09-22 Aarhus Universitet Antibodies towards an extracellular region of nbcn1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies

Non-Patent Citations (52)

* Cited by examiner, † Cited by third party
Title
Ando, I., Hoon, D. S. B., Suzuki, Y., Saxton, R. E., Golub, S. H., Irie, R. F. Ganglioside GM2 on the K56 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40:12 17, 1987. *
Bhattacharya Chatterjee, M., Pride, M. W., Seon, B. K., Kohler, H. Idiotype vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti idiotypes. J. Immunol 139:1354 1360, 1987. *
Bhattacharya-Chatterjee, M., Pride, M. W., Seon, B. K., Kohler, H. Idiotype vaccines against human T-cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes. J. Immunol 139:1354-1360, 1987.
Cahan, et al., "Identification of a human neuroectodermal tumor antigen (OFA-1-2) as ganglioside GD2," Proceedings National Academy of Sciences, vol. 79, pp. 7629-7633, Dec., 1982.
Cahan, et al., Identification of a human neuroectodermal tumor antigen (OFA 1 2) as ganglioside GD2, Proceedings National Academy of Sciences, vol. 79, pp. 7629 7633, Dec., 1982. *
Chen, H., Mittelman, A., Yamada, M. Association of restricted specificity of anti anti idiotypic antibodies with prolonged survival of melanoma patients. Proc Amer Assoc Clin Oncol 8:A1125, 1989. *
Chen, H., Mittelman, A., Yamada, M. Association of restricted specificity of anti-anti-idiotypic antibodies with prolonged survival of melanoma patients. Proc Amer Assoc Clin Oncol 8:A1125, 1989.
Dagleish, et al., "Antiidiotypic antibodies as immunogens: idiotype-based vaccines," Vaccine, vol. 6, pp. 215-220, Jun., 1988.
Dagleish, et al., Antiidiotypic antibodies as immunogens: idiotype based vaccines, Vaccine, vol. 6, pp. 215 220, Jun., 1988. *
Herlyn, D. Wettendorff, M. Schmoll, E. Anti idiotype immunization of cancer patients: modulation of immune response. Proc Natl Acad Sci 84:8055 8059, 1987. *
Herlyn, D. Wettendorff, M. Schmoll, E. Anti-idiotype immunization of cancer patients: modulation of immune response. Proc Natl Acad Sci 84:8055-8059, 1987.
Hoon, D. B. S., Ando, I., Sviland, G., Tsuchida, T., Okun, E., Morton, D. L., Irie, R. F. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine activated killer cells. Int J Cancer 43:857 862, 1989. *
Hoon, D. B. S., Irie, R. F., Cochran, A. J. Gangliosides from human melanoma immodulate response of T cells to interleukin 2. Cell Immunol 111:410 419, 1988. *
Irie, et al. "Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines", Proceedings National Academy of Sciences, vol. 79, pp. 5666-5670, Sep,. 1982.
Irie, et al. Human antibody to OFA I, a tumor antigen, produced in vitro by Epstein Barr virus transformed human B lymphoid cell lines , Proceedings National Academy of Sciences, vol. 79, pp. 5666 5670, Sep,. 1982. *
Irie, R. F., Matsuki, T., Morton, D. L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786 787, 1989. *
Irie, R. F., Matsuki, T., Morton, D. L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-787, 1989.
Irie, R. F., Morton, D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci 83:8694 8698, 1986. *
Jerne, N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373 389, 19794. *
Jerne, N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373-389, 19794.
Kahn, M., Hellstrom, I., Estin, C. D., Hellstrom, K. E., Monoclonal anti idiotypic antibodies related to the p97 melanoma antigen. Cancer Res 49:3157 3162, 1989. *
Kahn, M., Hellstrom, I., Estin, C. D., Hellstrom, K. E., Monoclonal anti-idiotypic antibodies related to the p97 melanoma antigen. Cancer Res 49:3157-3162, 1989.
Katano, M., Irie, R. F. Suppressed growth of human melanoma in nude mice by human monoclonal antibody to ganglioside GD2. Immunology Letters 8:169 174, 1984. *
Katano, M., Saxton, R. E., Irie, R. F. Human monoclonal antibody to tumor associated ganglioside GD2. J Clin Lab Immunol 15:119 126, 1984. *
Kusama, et al., "Syngeneic antiidiotypic antisera to murine antihuman high-molecular weight melanoma-associated antigen monoclonal antibodies," Cancer Research, vol. 47, pp. 4312-4317, Aug., 1987.
Kusama, et al., Syngeneic antiidiotypic antisera to murine antihuman high molecular weight melanoma associated antigen monoclonal antibodies, Cancer Research, vol. 47, pp. 4312 4317, Aug., 1987. *
Livingston, P. O. Experimental and clinical studies with active specific immunotherapy. In "Immunity to Cancer II" Eds M. S. Mitchell, Pub Alan L. Liss, Inc, N.Y. pp. 309-321 (1989).
Livingston, P. O. Experimental and clinical studies with active specific immunotherapy. In Immunity to Cancer II Eds M. S. Mitchell, Pub Alan L. Liss, Inc, N.Y. pp. 309 321 (1989). *
Livingston, P. O., Natoli, E. J., Calves, M. J., Stockert, E., Oettgen, H.F., Old, L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911 2915, 1987. *
Livingston, P. O., Natoli, E. J., Calves, M. J., Stockert, E., Oettgen, H.F., Old, L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987.
Nepom, et al., "Induction of immunity to a human tumor by in vivo administration of antiidiotype antibodies in mice," Proceedings National Academy of Sciences, vol. 81, pp. 2864-2867, May, 1984.
Nepom, et al., Induction of immunity to a human tumor by in vivo administration of antiidiotype antibodies in mice, Proceedings National Academy of Sciences, vol. 81, pp. 2864 2867, May, 1984. *
Ravindranath, M. H., Morton, D. L., Irie, R. F. An epitope common to ganglioside O acetyl AD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891 3897, 1989. *
Ravindranath, M. H., Morton, D. L., Irie, R. F. An epitope common to ganglioside O-acetyl AD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Canc
Ravindranath, M. H., Paulson, J. C., Irie, R. F. Human melanoma antigen O acetylated ganglioside GD3 is recognized by cancer autennarius lectin.1 J Biol Chem 263:2079 2086, 1988. *
Raychaudhuri, et al., "Potential role of antiidiotype antibodies in active tumor immunotherapy," Critical Review in Oncology/Hematology, vol. 9, issue 2, 1989.
Raychaudhuri, et al., Potential role of antiidiotype antibodies in active tumor immunotherapy, Critical Review in Oncology/Hematology, vol. 9, issue 2, 1989. *
Sikorska, H. M. Therapeutic applications of anti idiotypic antibodies. J Biol Res Mod 7:327 358, 1988. *
Sikorska, H. M. Therapeutic applications of anti-idiotypic antibodies. J Biol Res Mod 7:327-358, 1988.
Tai, et al., "Ganglioside GM2 as a human tumor antigen (OFA-I-1)", Proceedings of the National Academy of Sciences, vol. 80, pp. 5392-5396, Sep., 1983.
Tai, et al., Ganglioside GM2 as a human tumor antigen (OFA I 1) , Proceedings of the National Academy of Sciences, vol. 80, pp. 5392 5396, Sep., 1983. *
Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., Morton, D. L. Immunogenicity of melanoma associated gangliosides in cancer patients. Int J Cancer 35:607 612, 1985. *
Tai, T., Sze, L. L., Kawashima, I., Saxton, R. E., Irie, R. F. Monoclonal antibody detects monosialoganglioside having sialic acid 2 3 Galactosyl residue. J Biol Chem 262:6803 6807, 1987. *
This invention was made with Government support under Grant Nos. CA 30647, CA 42396 and CA 12582 awarded by the National Cancer Institute.
Tsuchida T., Saxton, R. E., Irie, R. F. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55 60, 1987. *
Tsuchida, T., Ravindranath, M. H., Saxton, R. E., Irie, R. F. Gangliosides of human melanoma: Altered expression in vivo and in vitro. Cancer Res 47:1278 1281, 1987. *
Tsuchida, T., Saxton, R. E., Morton, D. L., Irie, R. F. Gangliosides of human melanoma II. Cancer, 623:1166 1174, 1989. *
Tsuchida, T., Saxton, R. E., Morton, D. L., Irie, R. F. Gangliosides of human melanoma II. Cancer, 623:1166-1174, 1989.
Tsuchida, T., Saxton, R. E., Morton, D. L., Irie, R. F. Gangliosides of human melanoma. J Natl Cancer Inst 78:45 54, 1987. *
Viale, G., Grassi, F., Pelagi, M., Alzani, R., Menard, S., Miotti, S., Buffa, R., Gina, A., Siccardi, A. G. Anti human tumor antibodies induced in mice and rabbits by internal image anti idiotype monoclonal immunoglobulins. J Immunol 139:4250 4255, 1987. *
Viale, G., Grassi, F., Pelagi, M., Alzani, R., Menard, S., Miotti, S., Buffa, R., Gina, A., Siccardi, A. G. Anti-human tumor antibodies induced in mice and rabbits by "internal image" anti-idiotype monoclonal immunoglobulins. J Immunol 139:4250-4255, 1987.
Yano, T., Yasumoto, K., Nagashima, A., Murakami, H., Hashizume, S, and Nomoto, K. (1988) Immunohistological characterization of human monoclonal antibody against lung cancer. J Surg Oncol. 39, 108 113 (1988). *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0687295A1 (en) * 1993-02-26 1995-12-20 The Regents Of The University Of California Human b-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0687295A4 (en) * 1993-02-26 1997-01-15 Univ California Human b-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0702082A1 (en) * 1993-10-06 1996-03-20 Hagiwara, Yoshihide Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and dna base sequences encoding those sequences
US5589573A (en) * 1993-10-06 1996-12-31 Yoshihide Hagiwara Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
US6491914B1 (en) * 1993-12-09 2002-12-10 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US7517967B2 (en) 1995-01-17 2009-04-14 University Of Kentucky Research Foundation Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6509016B1 (en) 1995-01-17 2003-01-21 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US20050287148A1 (en) * 1995-01-17 2005-12-29 Malaya Chatterjee Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1996022373A3 (en) * 1995-01-17 1996-10-03 Univ Kentucky Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
WO1996022373A2 (en) * 1995-01-17 1996-07-25 University Of Kentucky Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
US20030114398A1 (en) * 1995-01-17 2003-06-19 Malaya Chatterjee Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US7399849B2 (en) 1995-01-29 2008-07-15 University Of Kentucky Research Foundation Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20060018895A1 (en) * 1995-01-29 2006-01-26 Malaya Chatterjee Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7083943B1 (en) 1995-01-29 2006-08-01 Malaya Chatterjee Polynucleotides related to murine anti-idiotype antibody 11D10 and methods of use thereof
WO1997019113A3 (en) * 1995-11-17 1997-09-25 Ct De Inmunologia Molecular Ci Monoclonal antiidiotypic antibodies (ab2) and uses thereof
WO1997019113A2 (en) * 1995-11-17 1997-05-29 Centro De Inmunologia Molecular (Cim) Monoclonal antiidiotypic antibodies (ab2) and uses thereof
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20030152575A1 (en) * 1997-06-13 2003-08-14 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
WO2000029443A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
EP2256199A1 (en) 1999-01-07 2010-12-01 ZymoGenetics, Inc. Therapeutic uses of BR43X2 soluble receptors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
EP2241623A2 (en) 1999-07-07 2010-10-20 ZymoGenetics, Inc. Monoclonal antibody against a human cytokine receptor
WO2001039788A2 (en) 1999-12-02 2001-06-07 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
US20020051103A1 (en) * 2000-06-26 2002-05-02 Faris Sadeg M. Backlight for a liquid crystal display having high light-recycling efficiency
US20020122795A1 (en) * 2000-12-08 2002-09-05 Paller Amy S. Compositions containing gangliosides for use in the treatment of skin disorders
US20080003617A1 (en) * 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
EP2192132A2 (en) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP3214095A1 (en) 2005-05-12 2017-09-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2399932A1 (en) 2005-05-12 2011-12-28 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US20070071760A1 (en) * 2005-08-09 2007-03-29 Herve Broly Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US20070274984A1 (en) * 2006-05-15 2007-11-29 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
EP3241846A1 (en) 2007-10-04 2017-11-08 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
EP2602263A2 (en) 2007-11-21 2013-06-12 Roskilde Universitet Polypeptides comprising an ice-binding activity
US20110027337A1 (en) * 2007-12-21 2011-02-03 Ifxa A/S Protease inhibitor
FR2944448A1 (en) * 2008-12-23 2010-10-22 Adocia STABLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE MONODONAL ANTIBODY AND AT LEAST ONE AMPHIPHILIC POLYSACHARIDE COMPRISING SUBSTITUENTS DERIVED FROM HYDROFOB ALCOHOLS OR HYDROPHOBIC AMINES.
CN102300586A (en) * 2008-12-23 2011-12-28 阿道恰公司 Stable Pharmaceutical Composition Containing At Least One Monoclonal Antibody And At Least One Amphiphilic Polysaccharide Comprising Hydrophobic Substituents
WO2010073119A1 (en) * 2008-12-23 2010-07-01 Adocia Stable pharmaceutical composition containing at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
US9493583B2 (en) 2009-12-23 2016-11-15 Adocia Anionic polysaccharides functionalized by a hydrophobic acid derivative
US20110172166A1 (en) * 2009-12-23 2011-07-14 Adocia Anionic polysaccharides functionalized by a hydrophobic acid derivative
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
WO2016146134A1 (en) 2015-03-16 2016-09-22 Aarhus Universitet Antibodies towards an extracellular region of nbcn1

Similar Documents

Publication Publication Date Title
US5208146A (en) Murine monoclonal anti-idiotype antibodies
US5419904A (en) Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
Alfonso et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients
Foon et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
US4876199A (en) Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US20100297008A1 (en) Ganglioside associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
EP0657471B1 (en) Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
Yamamoto et al. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3
Sen et al. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen et al. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2
Herlyn et al. Anti-idiotypic antibodies in cancer therapy
US5858361A (en) Monoclonal anti-idiotypic anti-CA125 antibodies and pharmaceutical compositions containing them
Basak et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside
Bhattacharya-Chatterjee et al. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer
Jinnohara et al. Anti‐tumor effect of internal image bearing anti‐idiotypic monoclonal antibody in relation to GM3 ganglioside
US6063379A (en) Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
Saito et al. Murine monoclonal anti-idiotype antibody (α) as a probe to detect human monoclonal antibody bound to human tumor tissues
US5854069A (en) GD2 anti-idiotypic antibodies and uses thereof
IE69384B1 (en) Novel antiidiotypic monoclonal antibodies
ES2274584T3 (en) ANTI-IDIOTIPIC MONOCLONAL ANTIBODIES, THEIR USE IN ACTIVE IMMUNOTHERAPY OF MALIGN TUMORS AND COMPOSITIONS CONTAINING THEMSELVES.
AU2003204088B2 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, 300

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:IRIE, REIKO F.;REEL/FRAME:005538/0629

Effective date: 19901102

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19970507

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA;REEL/FRAME:022013/0212

Effective date: 19910131

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA LOS ANGELES;REEL/FRAME:024748/0685

Effective date: 19910131

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362